Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 125 citing articles:

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
Mikhail Kosiborod, John Deanfield, Richard Pratley, et al.
The Lancet (2024) Vol. 404, Iss. 10456, pp. 949-961
Closed Access | Times Cited: 47
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Heart Journal (2024)
Open Access | Times Cited: 41
Heart failure with preserved ejection fraction
Carine E. Hamo, Colette DeJong, Nick Hartshorne‐Evans, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 36
Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials
Sanjiv J Shah, Kavita Sharma, Barry A. Borlaug, et al.
European Heart Journal (2024) Vol. 45, Iss. 35, pp. 3254-3269
Open Access | Times Cited: 30
Effect of Semaglutide on Cardiac Structure and Function in Patients With Obesity-Related Heart Failure
Scott D. Solomon, John W. Ostrominski, Xiaowen Wang, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1587-1602
Open Access | Times Cited: 23
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Richard E. Pratley, Katherine R. Tuttle, Peter Rossing, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1615-1628
Open Access | Times Cited: 22
Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial
Stephan von Haehling, Wolfram Doehner, Ruben Evertz, et al.
European Heart Journal (2024) Vol. 45, Iss. 37, pp. 3789-3800
Open Access | Times Cited: 20
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction
Morten Schou, Mark C. Petrie, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 3, pp. 247-257
Open Access | Times Cited: 19
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 9, pp. 773-785
Open Access | Times Cited: 18
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 18
Obesity and cardiovascular disease: an ESC clinical consensus statement
Konstantinos C. Koskinas, Emeline M. Van Craenenbroeck, Charalambos Antoniades, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 16
Inflammation in Obesity-Related HFpEF
Subodh Verma, Mark C. Petrie, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1646-1662
Open Access | Times Cited: 15
Integrated Management of Cardiovascular–Renal–Hepatic–Metabolic Syndrome: Expanding Roles of SGLT2is, GLP-1RAs, and GIP/GLP-1-RAs
Nikolaos Theodorakis, Maria Nikolaou
Biomedicines (2025) Vol. 13, Iss. 1, pp. 135-135
Open Access | Times Cited: 6
Heart Failure with Preserved Ejection Fraction
Antonio Cannatà, Theresa A. McDonagh
New England Journal of Medicine (2025) Vol. 392, Iss. 2, pp. 173-184
Closed Access | Times Cited: 4
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
Nikolaos Theodorakis, Maria Nikolaou
Biomolecules (2025) Vol. 15, Iss. 2, pp. 213-213
Open Access | Times Cited: 4
Did Finerenone Improve Health Status in the FINEARTS Trial?
Javed Butler, Muhammad Usman, Frank E. Harrell, et al.
Journal of the American College of Cardiology (2025) Vol. 85, Iss. 2, pp. 190-195
Closed Access | Times Cited: 2
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists in the Management of Obesity-Related Heart Failure with Preserved Ejection Fraction: Benefits beyond What Scales Can Measure?
Paschalis Karakasis, Nikolaos Fragakis, Dimitrios Patoulias, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2112-2112
Open Access | Times Cited: 14
Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis
Brendon L. Neuen, Robert A. Fletcher, Lauren Heath, et al.
Circulation (2024)
Open Access | Times Cited: 13
Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction
Subodh Verma, Javed Butler, Barry A. Borlaug, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1603-1614
Open Access | Times Cited: 12
Initiation and sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum
Izza Shahid, Muhammad Shahzeb Khan, Javed Butler, et al.
Heart Failure Reviews (2025)
Closed Access | Times Cited: 1
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
Melanie J. Davies, Peter van der Meer, Subodh Verma, et al.
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 1
State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age
Roy Rasalam, Andrew Sindone, Gary Deed, et al.
ESC Heart Failure (2025)
Open Access | Times Cited: 1
Acute heart failure – transitioning from symptom-based care to remission
Gad Cotter, Beth A. Davison, Douglas L. Mann, et al.
Journal of Cardiac Failure (2025)
Open Access | Times Cited: 1
Cardiovascular–Endocrine–Metabolic Medicine: Proposing a New Clinical Sub-Specialty Amid the Cardiometabolic Pandemic
Nikolaos Theodorakis, Maria Nikolaou, Andrew J. Krentz
Biomolecules (2025) Vol. 15, Iss. 3, pp. 373-373
Open Access | Times Cited: 1
GLP-1 RA for cardiometabolic risk reduction in obesity – How do we best describe benefit and value?
Sant Kumar, Michael J. Blaha
American Journal of Preventive Cardiology (2024) Vol. 18, pp. 100682-100682
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top